These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38730689)

  • 1. High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy.
    Kött J; Hoehne IL; Heidrich I; Zimmermann N; Reese KL; Zell T; Geidel G; Rünger A; Schneider SW; Pantel K; Smit DJ; Gebhardt C
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.
    Pedersen JG; Sokac M; Sørensen BS; Luczak AA; Aggerholm-Pedersen N; Birkbak NJ; Øllegaard TH; Jakobsen MR
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors.
    Stadler JC; Keller L; Mess C; Bauer AT; Koett J; Geidel G; Heidrich I; Vidal-Y-Sy S; Andreas A; Stramaglia C; Sementsov M; Haberstroh W; Deitert B; Hoehne IL; Reschke R; Haalck T; Pantel K; Gebhardt C; Schneider SW
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma.
    Hurkmans DP; Jensen C; Koolen SLW; Aerts J; Karsdal MA; Mathijssen RHJ; Willumsen N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
    Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
    Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
    van Not OJ; Verheijden RJ; van den Eertwegh AJM; Haanen JBAG; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kamphuis AM; Kapiteijn E; May AM; de Meza MM; Piersma D; van Rijn R; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Blokx WAM; Wouters MJM; Suijkerbuijk KPM
    JAMA Oncol; 2022 Dec; 8(12):1794-1801. PubMed ID: 36301521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
    Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
    J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab.
    Ma VT; Chamila Perera AA; Sun Y; Sitto M; Waninger JJ; Warrier G; Green MD; Fecher LA; Lao CD
    Front Immunol; 2022; 13():860421. PubMed ID: 35874737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
    Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA
    J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-
    Bai X; Dai J; Li C; Cui C; Mao L; Wei X; Sheng X; Chi Z; Yan X; Tang B; Lian B; Wang X; Zhou L; Li S; Kong Y; Qi Z; Xu H; Duan R; Guo J; Si L
    Front Oncol; 2021; 11():639085. PubMed ID: 34094921
    [No Abstract]   [Full Text] [Related]  

  • 17. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
    Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
    Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma.
    Ellebaek E; Khan S; Bastholt L; Schmidt H; Haslund CA; Donia M; Svane IM
    Eur J Cancer; 2024 Feb; 198():113476. PubMed ID: 38171116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.